A challenging diagnosis: hereditary angioedema presenting during pregnancy

Irene Chair MD, Gina Lacuesta MD, Christopher M. Nash MD MSc, Victoria Cook MD MSc

A 23-year-old pregnant woman (gravida 2, abortion/miscarriage 1, para 0) with a history of anxiety (treated with citalopram) and cocaine use (stopped before pregnancy) and no family history of swelling presented to hospital at 9 weeks gestation. She reported episodic abdominal pain and nausea, as well as vomiting and intermittent unilateral swelling of the hands and feet for the previous 2–4 days. An erythematous nonpruritic rash preceded her symptoms. During the pregnancy, she experienced 4 more episodes with similar symptoms, presenting to either her prenatal care provider or the emergency department. At each presentation, she was assessed for pregnancy complications and reassured that her symptoms would improve postpartum.

The patient delivered a healthy female infant at term by cesarean delivery under spinal anesthetic and was discharged on postpartum day 2. Eleven days postpartum, the patient presented with swelling and erythema at the cesarean delivery wound. She was diagnosed with cellulitis and managed with intravenous (IV) ceftriaxone, followed by oral antibiotics for 2 weeks with improvement. A wound culture grew Enterobacter cloacae. A few days later, she returned with abdominal pain and pronounced swelling of the left labia and right thigh. A computed tomography (CT) scan of the abdomen and pelvis showed inflammatory changes at the cesarean delivery site with no visible abscess, and nonspecific retroperitoneal inflammatory changes. Her symptoms progressed to include vomiting, diarrhea, abdominal distension and tenderness. She was tachycardic and volume depleted and did not respond to ondansetron and fluid bolus, prompting admission under obstetrics for potential wound infection. Wound examination identified incision breakdown with purulent discharge; wound swab returned polymicrobial flora and was considered nondiagnostic. Clostridiooides difficile polymerase chain reaction (PCR) testing of stool was positive, but no toxin was detected. Repeat CT scan showed bowel wall thickening and edema involving the left mid small bowel, with moderate free fluid. Her symptoms were attributed to the wound and C. difficile infection, the infectious disease team recommended ceftriaxone and metronidazole, and she gradually improved over 1 week. She underwent vacuum-assisted closure of the wound and ceftriaxone, followed by oral antibiotics for 2 weeks with improvement.

Over the next 9 months, the patient continued to have symptoms of abdominal pain, nausea, vomiting and episodic, migratory swelling, resulting in frequent presentations to health care providers (Figure 1 and Table 1). In total, she had 6 emergency department presentations and 1 hospital admission and saw 5 different specialists, including obstetrics and gynecology, internal medicine, 2 infectious disease specialists and gastroenterology. She underwent extensive investigations and various diagnoses were suggested (Table 1). Multiple specialists documented her episodes of swelling, but a diagnosis of angioedema was not considered, and no trials of therapies for possible histamine-mediated angioedema (Table 2) were initiated. The patient did not take any angiotensin-converting enzyme (ACE) inhibitor or exogenous estrogen that could have confounded the clinical presentations.

At 10 months postpartum, she was assessed in an outpatient infectious disease clinic, where C4 and C1 inhibitor (INH) levels were ordered. Consistent with a diagnosis of hereditary angioedema (HAE), C1-INH functional assay and C4 were reduced on 2 separate occasions at 10 and 11 months postpartum (C1-INH: 0.18 and 0.37 U/mL, respectively [normal 0.7–1.3 U/mL]; C4: 0.06 and 0.07 g/L, respectively [normal 0.09–0.5 g/L]). A C1-INH antigen level assay was not performed because the test was not available in the province where she lived. She was referred to Allergy and Clinical Immunology and underwent repeat C1-INH and C4 testing, which remained low. Genetic testing identified a
previously unreported missense mutation in exon 8 of SERPING1:
c1475T > C, p.(Met492Thr) (classified as a likely pathogenic variant)
and we diagnosed type 1 HAE (HAE-1). The patient has responded
well to prophylactic C1-INH therapy and icatibant (a selective brady-
kinin 2 receptor antagonist) as needed for breakthrough swelling.

Discussion

Hereditary angioedema is an autosomal dominant disorder that
affects about 1 in 50 000 individuals. It presents with intermit-
tent episodes of painful, asymmetric swelling without urticaria
that affect the extremities and bowel mucosa (in more than 90% of patients).
The face, genitals and upper airways are also frequently affected.
In about 25% of patients, a nonpruritic erythematous rash (ery-
the ma marginatum) precedes the edema. Hereditary angio-
edema is distinct from the more common histamine-mediated
angioedema, which is generally associated with urticaria and
pruritus, fast onset and offset of symptoms, and response to
antihistamines, epinephrine or corticosteroids (Table 2).

Causes and types of HAE

Most cases of HAE are a result of deficiency or dysfunction in
C1-INH — a plasma protease inhibitor that mediates the production
of the vasodilator bradykinin. Hereditary angioedema attacks can
be triggered by minor trauma, stress or hormonal changes (e.g.,
pregnancy, menstruation or use of oral contraceptives) leading to
increased levels of bradykinin, which increase vascular permeabil-
ity and cause angioedema.

Figure 1: Timeline of swelling episodes and presentations to the emergency department (ED) during the postpartum period of a 23-year-old woman. Note: + = positive, C. difficile = Clostridioides difficile, C1-INH = C1 inhibitor, CT = computed tomography, H (1 wk) = hospital admission of 1-week duration, H. pylori = Helicobacter pylori, HAE = hereditary angioedema, PCR = polymerase chain reaction, S = swelling episodes (including vulvar and periph-
eral [hands, feet, limbs]) documented on assessment or reported by the patient, US = ultrasound.
Although our patient had classic symptoms of HAE, several factors likely contributed to the delay in diagnosis, including pregnancy, past substance use, lack of facial edema, lack of family history and age at presentation. Most patients have onset of symptoms in childhood and adolescence, but some present for the first time during pregnancy. A retrospective review of 125 full-term pregnancies in women symptomatic with HAE found that 71% had no previous diagnosis of HAE. In most, the diagnosis was not made until several years after the pregnancy. Pregnancy can increase, decrease or have no effect on the number or severity of HAE attacks.

### Table 1: Postpartum investigations, results, diagnoses and management in a 23-year-old woman

| Month postpartum | Investigation | Result | Diagnosis | Management |
|------------------|---------------|--------|-----------|------------|
| 1                | CT scan       | Inflammatory changes at cesarean delivery site, no abscess. Nonspecific retroperitoneal inflammatory change | Wound infection | IV antibiotics (ceftriaxone) |
| 1                | CT scan       | Bowel wall thickening and edema left mid small bowel | | |
|                  | Vulvar ultrasound for unilateral labial edema | Edema | | |
| 2                | Stool culture | PCR + for *C. difficile* | *C. difficile* | Metronidazole |
|                  |               | Toxin negative | | |
| 6                | Ultrasound (pelvic, vulvar) | Unremarkable (no mass, edema) | Uncertain | None |
|                  | Stool culture | Adenovirus | Gastroenteritis | IV fluids |
| 7                | *H. pylori* breath test | Positive for *H. pylori* | *H. pylori* | Amoxicillin, pantoprazole, levofloxacin |
|                  | Stool culture | PCR + *C. difficile* | *C. difficile* | Vancomycin |
|                  |               | Toxin negative | | |
| 8                | CT scan       | Extensive bowel wall thickening of distal ileum, moderate free fluid | Possible inflammatory bowel disease | Gastroenterology referral |
| 9                | Upper and lower endoscopy | Mild colitis (areas affected on CT were normal) | Nonspecific colitis | Infectious Disease referral for possible unusual infection |

Note: *C. difficile* = *Clostridioides difficile*, CT = computed tomography, *H. pylori* = *Helicobacter pylori*, IV = intravenous, PCR + = positive polymerase chain reaction test.

*Detected on PCR, no toxin, suspicious for colonization rather than infection but decision to treat per Infectious Disease.

### Table 2: Clinical features differentiating bradykinin-mediated HAE and histamine-mediated angioedema

| Features | Hereditary angioedema (bradykinin-mediated) | Histamine-mediated angioedema |
|----------|--------------------------------------------|-------------------------------|
| Age of onset | Often first to second decades | Any |
| Speed of onset | Hours | Minutes |
| Attack duration (without treatment) | 3–5 d | Several hours |
| Predominant attack location | Extremities, face, upper airways, genitourinary tract, gastrointestinal tract or bowel wall | Anywhere, although face (eyelids, lips) and extremities are common |
| Urticaria or pruritus | Rare, can have erythema marginatum | Common |
| Abdominal pain or swelling | Common | Rare |
| Triggering factors | Trauma, infections, stress, hormonal changes (e.g., estrogen, pregnancy), ACE-i; can also be random | Allergies, infections, stress, NSAIDs or ASA; often spontaneous |
| Response to antihistamines, corticosteroids and epinephrine | No | Yes |

Note: ACE-i = angiotensin-converting enzyme inhibitor, ASA = acetylsalicylic acid, HAE = hereditary angioedema, NSAID = nonsteroidal anti-inflammatory drug.
Despite our patient having clear evidence of bowel wall edema on CT scans and impressive, asymmetric swelling in the extremities and labia, the edema was never questioned or documented as angioedema, and no trials of therapy were considered. Our patient is one of the approximately 25% of patients with HAE who do not present with facial swelling during attacks; facial swelling is more easily recognized as angioedema.5

**Screening and diagnosis of HAE**

Diagnostic laboratory tests for HAE are readily available and inexpensive. They include measuring plasma levels of complement C4 and C1-INH antigen and function (Table 3). C1-INH can be temporarily low in pregnancy even in patients without HAE; therefore, testing should be repeated postpartum for confirmation.5,4 Genetic testing should be considered in the absence of family history (as in our case) or if all diagnostic tests are normal (as in the case of HAEnC-INH) and there is still clinical suspicion of HAE.

**Management of HAE**

Pharmacologic treatment for HAE includes on-demand therapy to reduce the severity and duration of an attack, short-term prophylaxis before exposure to a known or possible trigger, and long-term prophylaxis to reduce the risk of attacks and associated morbidity (see Table 4 for guideline-recommended treatments).3,4 With proper medical management in collaboration with an HAE specialist, successful pregnancy and delivery are possible in people with HAE.4 During pregnancy, delivery and breastfeeding, guidelines recommend plasma-derived C1-INH (a blood product

---

**Table 3: Three types of HAE: prevalence and laboratory findings**

| Types of HAE | Prevalence among patients with HAE | Laboratory findings |
|--------------|-----------------------------------|---------------------|
| HAE-1        | About 85% (most common)           | ↓                   |
| HAE-2        | About 15%                         | ↓                   |
| HAEnC-INH    | Exact prevalence unknown (estimated to be < 1%) | Normal |

Note: C1-INH = C1 inhibitor, HAE-1 = type 1 hereditary angioedema, HAE-2 = type 2 hereditary angioedema, HAEnC-INH = hereditary angioedema with normal C1 inhibitor.

*The availability of assays used to diagnose HAE varies across provinces.

Adapted from: Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema guideline. Allergy Asthma Clin Immunol 2019;15:72.

**Table 4: Guideline-recommended treatments for HAE available in Canada that are supported by high-level evidence**

| HAE-specific treatment | Brand name | Mechanism of action | Approved indications in Canada | Dose and route of administration | Age indications |
|------------------------|------------|---------------------|-------------------------------|----------------------------------|-----------------|
| Plasma-derived C1-INH*  | Berinert  | Replaces C1-INH     | Acute treatment               | 20 U/kg IV as needed             | Children, adolescents and adults |
|                        | Cinryze   | Replaces C1-INH     | Long-term prophylaxis         | 1000 U IV every 3–4 d            | Adolescents and adults            |
|                        | Haegarda  | Replaces C1-INH     | Long-term prophylaxis         | 60 U/kg body weight twice weekly (every 3–4 d) | Adolescents and adults            |
| Icatibant              | Firazyr   | Synthetic selective and specific antagonist of bradykinin 2 receptor | Acute treatment               | 30 mg SC injection as needed; dose-adjusted for adolescents < 65 kg and children ≥ 2 yr† | Children, adolescents and adults |
| Lanadelumab            | Takhyro   | Fully human monoclonal antibody that binds plasma kallikrein and inhibits its proteolytic activity | Long-term prophylaxis         | 300 mg SC injection every 2 wk A dosing interval of 300 mg every 4 wk may be considered if the patient is well controlled (e.g., attack free) for more than 6 mo | Adolescents and adults |

Note: IV = intravenous, SC = subcutaneous.

*Treatment of choice during pregnancy, delivery and breast-feeding.

†12 kg to 25 kg: 10 mg (1.0 mL); 26 kg to 40 kg: 15 mg (1.5 mL); 41 kg to 50 kg: 20 mg (2.0 mL); 51 kg to 65 kg: 25 mg (2.5 mL); > 65 kg: 30 mg (3.0 mL).

Adapted from: Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema guideline. Allergy Asthma Clin Immunol 2019;15:72.
that replaces the deficient C1-INH) for both on-demand and prophylactic treatment, given its long history of efficacy and safety.\(^3\) When used as indicated, plasma-derived C1-INH products are well tolerated, with no documented transmission of infectious agents.\(^3\) Other treatments in pregnancy (Table 4) could be considered based on shared decision-making with the patient.

Given the risk of an attack, pregnant patients with HAE should deliver in hospital and be closely monitored for at least 72 hours after delivery. Vaginal delivery and epidural anesthesia are preferred because surgery or general anesthesia with endotracheal intubation may trigger swelling.\(^3,4\) Plasma-derived C1-INH should be available on the birthing unit for on-demand use if required.

**Screening of offspring**

Offspring of patients with HAE should be screened. Because C1-INH levels can be falsely low in the first year of life, confirmatory testing should be done after age 1 year.\(^3,4\)

**Resources for patients and health care professionals**

A patient organization, HAE Canada (https://haecanada.org/), provides resources for patients and caregivers. The Canadian Hereditary Angioedema Network (https://chaen-rcah.ca/) is a physician organization that also provides resources for patients and health care professionals, including contact information for HAE specialists across Canada.

**References**

1. Munneh N, Tick M, Borum M. Angioedema with severe acute abdominal pain: think of hereditary angioedema. Clin Res Hepatol Gastroenterol 2021;45:101702.
2. Jacobs J, Neeno T. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency. Postgrad Med 2021;133:639-50.
3. Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema guideline. Allergy Asthma Clin Immunol 2019;15:72.
4. Chair II, Binkley KE, Betschel SD. Hereditary angioedema in pregnancy. Obstet Gynecol Surv 2021;76:566-74.
5. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-74.
6. Starr JC, Brasher GW, Rao A, et al. Erythema marginatum and hereditary angioedema. South Med J 2004;97:948-50.
7. Banday AZ, Kaur A, Jindal AK, et al. An update on the genetics and pathogenesis of hereditary angioedema. Genes Dis 2019;7:75-83.
8. Bork K, Machnig T, Wulff K, et al. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis 2020;15:289.
9. Banerji A, Busse P, Christiansen SC, et al. Current state of hereditary angioedema management: a patient survey. Allergy Asthma Proc 2015;36:213-7.
10. Martinez-Saguer I, Rusieck E, Äygören-Pürsün E, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 2010;203:131.e1-7.
11. The voice of the patient: hereditary angioedema. Silver Spring (MD): Center for Biologics Evaluation and Research (CBER); U.S. Food and Drug Administration (FDA); 2018. Available: https://www.fda.gov/media/113509/download (accessed 2022 Mar 10).
12. González-Quevedo T, Larco JI, Marcos C, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin Immunol 2016;26:161-7.